BIIB

Biogen Inc

• Simply Wall St·31m ago

  Is It Time To Reassess Biogen (BIIB) After Its 49% One Year Share Price Surge

• Seeking Alpha·11h ago

  CEO of top pharma lobby PhRMA to resign: Endpoints News

• Benzinga·1d ago

  Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward

• Reuters·1d ago

  BIOGEN <BIIB.O>: RBC CUTS TARGET PRICE TO $213 FROM $233

• Simply Wall St·1d ago

  Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook

• Benzinga·1d ago

  Biogen Teams Up With Alloy To Develop Next-Gen RNA Drugs, Targets Hard-To-Reach Diseases With Advanced Antisense Technology

• Reuters·1d ago

  ALLOY: THROUGH THIS COLLABORATION, BIOGEN WILL APPLY PLATFORM TO ADVANCE ANTISENSE THERAPEUTICS AGAINST MULTIPLE UNDISCLOSED TARGETS

• Reuters·1d ago

  U.S. RESEARCH ROUNDUP-Centerspace, Union Pacific, XPO

• NASDAQ·2d ago

  American Water Works Takes Over #314 Spot From Biogen

• Reuters·2d ago

  Biogen to report first-quarter financial results, host webcast with management

• Seeking Alpha·2d ago

  Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease

• Seeking Alpha·2d ago

  Biogen flags ~$0.19 hit to Q1 net income per share

• TipRanks·2d ago

  Biogen expects Q1 results to include $34M expense on pre-tax basis

• Benzinga·2d ago

  Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get

• Benzinga·2d ago

  Biogen Flags $34M R&D Charge to Hit Q1 Earnings by $0.19 Per Share